Throughout the development in the clinical application of epigenetic inhibitors in SCLC and NEPC, we can conclude that DNA damage response inhibitors of PARP and ATR inhibitors have shown promising antitumor activity. The gene discussed is PARP1; the disease is small cell lung carcinoma.